Mesoblast Appoints New CFO to Strengthen Commercial Expansion

Mesoblast Limited (ASX: MSB) has named James M. O’Brien as its U.S.-based Chief Financial Officer, a move that underscores the company’s ongoing transition toward functioning as a fully integrated commercial enterprise. O’Brien brings extensive financial management experience across global life sciences and pharmaceutical companies, including senior roles at Actavis, Allergan, Nycomed, Cognition Therapeutics, and Faron Pharmaceuticals. His background spans corporate finance, forecasting, acquisitions, and operational oversight, with involvement in transactions exceeding AU$10 billion.

Mesoblast’s leadership highlighted that O’Brien’s expertise will support the commercialization of Ryoncil®, the first FDA-approved mesenchymal stromal cell therapy for pediatric SR-aGvHD, while strengthening governance and financial controls. The company continues advancing its allogeneic cell therapy pipeline targeting inflammatory conditions, heart failure, and chronic low back pain, supported by an extensive global patent portfolio and international commercial partnerships.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com